11
DEC
2019

Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit

Posted By :
Comments : Off
For Immediate Release on Wednesday, December 11, 2019 Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit NW Bio CTO To Highlight History Of DCVax®-L and Phase III Clinical Trial BETHESDA, Md., December 11, 2019 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that...
Read More
10
OCT
2019

NW Bio Moves Forward With SEC Settlement

Posted By :
Comments : Off
BETHESDA, MD, October 10, 2019 – Northwest Biotherapeutics (NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with the SEC.   As previously reported, the Company has been investigated by the SEC and has cooperated with the investigation. The Company has now successfully entered into a settlement agreement with the SEC...
Read More
04
SEP
2019

NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations

Posted By :
Comments : Off
Specialist in Immuno-Oncology; Previously Research Scientific Director In Merck’s Keytruda® Program BETHESDA, MD, September 4, 2019 – Northwest Biotherapeutics (NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has expanded its senior management team with the addition of Dr. Kevin T. Duffy as Vice President, Medical Affairs and External...
Read More
04
JUN
2019

Highlights Of NW Bio’s Program Update In The Industry Expert Theater Presentation At ASCO

Posted By :
Comments : Off
BETHESDA, Md., June 4, 2019 /PRNewswire/ — Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today highlights from Dr. Marnix Bosch’s Program Update in the Industry Expert Theater presentation at the 55th annual ASCO Conference, which was publicly webcast and was posted on the home page of the Company’s websit...
Read More
30
MAY
2019

NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO

Posted By :
Comments : Off
Follow-Up Data From The Phase I Trial Of DCVax®-Direct, and Progress Report On The Road To Unblinding The DCVax®-L Phase III GBM Trial  BETHESDA, Md., May 30, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 2, 2019 at 4:15 p.m. CDT (Chicago Time) in the Industry Expert Showcase Theater in the exhibit...
Read More